Patents by Inventor John S. McMurray
John S. McMurray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10385080Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.Type: GrantFiled: August 16, 2017Date of Patent: August 20, 2019Assignees: Board of Regents, The University of Texas System, Baylor College of MedicineInventors: John S. McMurray, Pijus Kumar Mandal, Pietro Morlacchi, Morgan Knight, David B. Corry
-
Publication number: 20180222931Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.Type: ApplicationFiled: August 16, 2017Publication date: August 9, 2018Applicants: Board of Regents, The University of Texas System, Baylor College of MedicineInventors: John S. McMURRAY, Pijus Kumar MANDAL, Pietro MORLACCHI, Morgan KNIGHT, David B. CORRY
-
Patent number: 9765099Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.Type: GrantFiled: May 8, 2014Date of Patent: September 19, 2017Assignees: Board of Regents, The University of Texas System, Baylor College of MedicineInventors: John S. McMurray, Pijus Kumar Mandal, Pietro Morlacchi, Morgan Knight, David B. Corry
-
Publication number: 20160145279Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.Type: ApplicationFiled: May 8, 2014Publication date: May 26, 2016Applicants: Baylor College of Medicine, Board of Regents, The University of Texas SystemInventors: John S. McMURRAY, Pijus Kumar MANDAL, Pietro MORLACCHI, Morgan KNIGHT, David B. CORRY
-
Patent number: 8841257Abstract: Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such as the platelet-derived growth factor, the epidermal growth factor, vascular endothelial growth factor, and other signaling molecules such as leptin. Blocking these interactions prevents STAT3 from being phosphorylated on Tyr705, which is required for the dimerization of STAT3, translocation to the nucleus, binding to STAT3 response elements on promotors, and transcription of genes. In addition to these activities, binding to the SH2 domain of STAT3 breaks up pre-formed dimmers, thereby preventing the transcriptional activity of the inhibitor.Type: GrantFiled: April 9, 2010Date of Patent: September 23, 2014Assignee: Board of Regents, The University of Texas SystemInventors: John S. McMurray, Pijus K. Mandal, Warren S. Liao, Fredika Robertson, Xiaomin Chen, Ramesh Rajaopal, Zhiyong Ren
-
Publication number: 20120035114Abstract: Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such as the platelet-derived growth factor, the epidermal growth factor, vascular endothelial growth factor, and other signaling molecules such as leptin. Blocking these interactions prevents STAT3 from being phosphorylated on Tyr705, which is required for the dimerization of STAT3, translocation to the nucleus, binding to STAT3 response elements on promotors, and transcription of genes. In addition to these activities, binding to the SH2 domain of STAT3 breaks up pre-formed dimmers, thereby preventing the transcriptional activity of the inhibitor.Type: ApplicationFiled: April 9, 2010Publication date: February 9, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: John S. McMurray, Pijus K. Mandal, Warren S. Liao, Fredika Robertson, Xiaomin Chen, Ramesh Rajaopal, Zhiyong Ren
-
Patent number: 6923993Abstract: The present invention is directed to a process of isolating an extract from a Euphorbia obesa (EO) plant by: preparing a sample of said plant comprising removal of the latex material; dissolving said sample with first solvent to form a solution; separating said solution into a liquid and a pulp fraction; and purifying said pulp fraction. The isolated EO extract induces apoptosis and inhibits growth of a cancerous cell. Thus, the present invention is also directed to a method for inducing apoptosis and growth inhibition of a cancerous cell by contacting the cell with an effective amount of the EO extract by the process of the invention. Preferably, the extract is administered both to the tumor directly and intravenously. The preferred lines of cancerous cells are melanoma, non-small cell lung cancer, prostate cancer, breast carcinoma, ovarian cancer, lymphoma and leukemia cells.Type: GrantFiled: December 12, 2001Date of Patent: August 2, 2005Inventors: Nicholas D. Donato, Nicholas J. Donato, David C. Sample, Margot Perez, John S. McMurray, Robert A Newman
-
Publication number: 20030118677Abstract: The present invention is directed to a process of isolating an extract from a Euphorbaciae obesa (EO) plant by: preparing a sample of said plant comprising removal of the latex material; dissolving said sample with first solvent to form a solution; seperating said solution into a liquid and a pulp fraction; and purifying said pulp fraction. The isolated EO extract induces apoptosis and inhibits growth of a cancerous cell. Thus, the present invention is also directed to a method for inducing apoptosis and growth inhibition of a cancerous cell by contacting the cell with an effective amount of the EO extract by the process of the invention. Preferably, the extract is administered both to the tumor directly and intravenously. The preferred lines of cancerous cells are melanoma, non-small cell lung cancer, prostate cancer, breast carcinoma, ovarian cancer, lymphoma and leukemia cells.Type: ApplicationFiled: December 12, 2001Publication date: June 26, 2003Applicant: Credere CorporationInventors: Nicholas D. Donato, Nicholas J. Donato, David C. Sample, Margot Perez, John S. McMurray, Robert A. Newman
-
Patent number: 6177405Abstract: The useful cyclic peptides cyclo[Thr-Lys-Pro-Arg-Gly] and cyclo[Thr-Lys-Pro-Arg-Asp] are disclosed.Type: GrantFiled: July 22, 1992Date of Patent: January 23, 2001Inventors: Kenji Nishioka, John S. McMurray, B. Montgomery Pettitt, Fahad Al-Obeidi